Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sorafenib in Persistent or Recurrent Ovarian or Primary Peritoneal Carcinoma
NCT00093626Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Oct 2004
- Primary completion
- Sep 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sorafenib in ovarian carcinoma and primary peritoneal carcinoma (PPC), sponsored by National Cancer Institute. Primary endpoints: Frequency and severity of adverse events as assessed by CTCAE v3.0 up to 5 years and Progression-free survival at 6 months. Started Oct 2004; status: completed.
02
Drugs
sorafenib
03
Conditions
ovarian carcinomaprimary peritoneal carcinoma (PPC)
Beyond the preview
Go deeper on NCT00093626.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00093626.